No products in the cart.
Pre-made Alomfilimab benchmark antibody ( Whole mAb, anti-ICOS therapeutic antibody, Anti-AILIM/CD278/CVID1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-017
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Alomfilimab biosimilar, Whole mAb, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Alomfilimab biosimilar, Whole mAb, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody |
|---|---|
| INN Name | Alomfilimab |
| Target | ICOS |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 7joo:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Kymab |
| Conditions Approved | NA |
| Conditions Active | Gastic cancers,Non-small cell lung cancer,Melanoma,Hepatocellular carcinoma,Esophageal cancer,Head and neck squamous cell carcinoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ICOS |
| Package |
Previous slide
Next slide
